Apeiron is built on a financial base that has been provided by national and international private equity investors. In 2010, GSK joined the existing shareholders by acquiring a minority stake in the company. Additionally, Apeiron has received financial support from the following institutions / programs:

Austria Wirtschaftsservice (AWS)

vienna business agency

Österreichische Forschungsförderungsgesellschaft (FFG)

Wirtschaftskammern Österreichs (WKO)

Eurothymaide

EUGeneHeart